Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Language
Publication year range
1.
Med Mycol Case Rep ; 36: 31-34, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35585870

ABSTRACT

Sporotrichosis is a global occurring implantation (subcutaneous) mycosis, caused by Sporothrix species, usually affecting the skin and the lymphatic vessels, from where it can disseminate. Nowadays, the vast majority of sporotrichosis infections in Brazil are caused by zoonotic transmission of S. brasiliensis which is the main etiologic agent. We report a cutaneous disseminated case of this disease, observed in an immunocompetent farmer living in southern Brazil, the Sporothrix schenckii-infection was successfully treated with itraconazole.

2.
J Med Microbiol ; 67(4): 560-569, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29461182

ABSTRACT

PURPOSE: Cryptococcosis is acquired from the environment by the inhalation of Cryptococcus cells and may establish from an asymptomatic latent infection into pneumonia or meningoencephalitis. The genetic diversity of a Cryptococcus neoformans species complex has been investigated by several molecular tools, such as multi-locus sequence typing, amplified fragment length polymorphism (AFLP), restriction fragment length polymorphism and microsatellite analysis. This study aimed to investigate the genotype distributions and antifungal susceptibility profiles of C. neoformans sensu lato isolates from southern Brazil. METHODOLOGY: We studied 219 C. neoformans sensu lato isolates with mating- and serotyping, AFLP fingerprinting, microsatellite typing and antifungal susceptibility testing.Results/Key findings. Among the isolates, 136 (69 %) were from HIV-positive patients. Only C. neoformans mating-type α and serotype A were observed. AFLP fingerprinting analysis divided the isolates into AFLP1/VNI (n=172; 78.5 %), AFLP1A/VNII (n=19; 8.7 %), AFLP1B/VNII (n=4; 1.8 %) and a new AFLP pattern AFLP1C (n=23; 10.5 %). All isolates were susceptible to tested antifungals and no correlation between antifungal susceptibility and genotypes was observed. Through microsatellite analysis, most isolates clustered in a major microsatellite complex and Simpson's diversity index of this population was D=0.9856. CONCLUSION: The majority of C. neoformans sensu stricto infections occurred in HIV-positive patients. C. neoformans AFLP1/VNI was the most frequent genotype and all antifungal drugs had high in vitro activity against this species. Microsatellite analyses showed a high genetic diversity within the regional C. neoformans sensu stricto population, and correlation between environmental and clinical isolates, as well as a temporal and geographic relationship.


Subject(s)
Antifungal Agents/pharmacology , Cryptococcosis/microbiology , Cryptococcus neoformans/drug effects , Cryptococcus neoformans/isolation & purification , Drug Resistance, Fungal , Amplified Fragment Length Polymorphism Analysis , Brazil , Cryptococcus neoformans/classification , Cryptococcus neoformans/genetics , Genotype , Humans , Microbial Sensitivity Tests , Multilocus Sequence Typing , Phylogeny , Polymorphism, Restriction Fragment Length
3.
Braz. j. microbiol ; 47(2): 373-380, Apr.-June 2016. tab, graf
Article in English | LILACS | ID: lil-780822

ABSTRACT

Abstract Vulvovaginal candidiasis affects women of reproductive age, which represents approximately 15–25% of vaginitis cases. The present study aimed to isolate and characterize yeast from the patients irrespective of the presentation of clinical symptoms. The isolates were subjected to in vitro susceptibility profile and characterization by molecular markers, which intended to assess the distribution of species. A total of 40 isolates were obtained and identified through the CHROMagar, API20aux and by ITS and D1/D2 regions sequencing of DNAr gene. Candida albicans strains were genotyped by the ABC system and the isolates were divided into two genotypic groups. The identity of the C. albicans, C. glabrata, C. guilliermondii, C. kefyr and Saccharomyces cerevisiae isolates was confirmed by the multilocus analysis. The strains of Candida, isolated from patients with complications, were found to be resistant to nystatin but sensitive to fluconazole, amphotericin B and ketoconazole, as observed by in vitro sensitivity profile. The isolates from asymptomatic patients, i.e., the colonized group, showed a dose-dependent sensitivity to the anti-fungal agents, fluconazole and amphotericin B. However, the isolates of C. albicans that belong to distinct genotypic groups showed the same in vitro susceptibility profile.


Subject(s)
Humans , Female , Adolescent , Adult , Middle Aged , Young Adult , Candida/drug effects , Candidiasis, Vulvovaginal/microbiology , Antifungal Agents/pharmacology , Patients/statistics & numerical data , Candida/isolation & purification , Candida/classification , Candida/genetics , Microbial Sensitivity Tests , Fluconazole/pharmacology , Drug Resistance, Fungal
4.
Braz J Microbiol ; 47(2): 373-80, 2016.
Article in English | MEDLINE | ID: mdl-26991298

ABSTRACT

Vulvovaginal candidiasis affects women of reproductive age, which represents approximately 15-25% of vaginitis cases. The present study aimed to isolate and characterize yeast from the patients irrespective of the presentation of clinical symptoms. The isolates were subjected to in vitro susceptibility profile and characterization by molecular markers, which intended to assess the distribution of species. A total of 40 isolates were obtained and identified through the CHROMagar, API20aux and by ITS and D1/D2 regions sequencing of DNAr gene. Candida albicans strains were genotyped by the ABC system and the isolates were divided into two genotypic groups. The identity of the C. albicans, C. glabrata, C. guilliermondii, C. kefyr and Saccharomyces cerevisiae isolates was confirmed by the multilocus analysis. The strains of Candida, isolated from patients with complications, were found to be resistant to nystatin but sensitive to fluconazole, amphotericin B and ketoconazole, as observed by in vitro sensitivity profile. The isolates from asymptomatic patients, i.e., the colonized group, showed a dose-dependent sensitivity to the anti-fungal agents, fluconazole and amphotericin B. However, the isolates of C. albicans that belong to distinct genotypic groups showed the same in vitro susceptibility profile.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Candidiasis, Vulvovaginal/microbiology , Adolescent , Adult , Candida/classification , Candida/genetics , Candida/isolation & purification , Drug Resistance, Fungal , Female , Fluconazole/pharmacology , Humans , Microbial Sensitivity Tests , Middle Aged , Patients/statistics & numerical data , Young Adult
5.
Rev. iberoam. micol ; 32(4): 221-228, oct.-dic. 2015. tab, ilus
Article in English | IBECS | ID: ibc-143440

ABSTRACT

Background. Candida species are the main cause of hospital acquired fungal bloodstream infections. The main risk factors for candidemia include parenteral nutrition, long-term intensive care, neutropenia, diabetes, abdominal surgery and the use of central venous catheters. The antifungal drugs used to treat candidemia are mainly the echinocandins, however some isolates may be resistant to these drugs. Aims. This work aims to evaluate the in vitro susceptibility patterns of various Candida species isolated from blood samples and provide their identification by molecular characterization. Methods. Antifungal susceptibility testing was performed using the broth microdilution method. The sequencing of the ITS and D1/D2 regions of rDNA was used for molecular characterization. Results. Seventy-four of the 80 isolates were susceptible to anidulafungin, 5 were intermediate, and 1 was resistant. For micafungin 67 were susceptible, 8 were intermediate and 5 were resistant. All isolates were susceptible to amphotericin B. Lastly, 65 isolates were susceptible to fluconazole, 8 were dose-dependent and 4 were resistant. The molecular identification corroborated the phenotypic data in 91.3% of the isolates. Conclusions. Antifungal susceptibility data has an important role in the treatment of candidemia episodes. It was also concluded that the molecular analysis of isolates provides an accurate identification and identifies genetic variability within Candida species isolated from patients with candidemia (AU)


Antecedentes. Los hongos del género Candida son la causa principal de infección micótica del torrente sanguíneo adquirida en el hospital. Entre los factores de riesgo asociados a la candidemia destacan la nutrición parenteral, la estancia prolongada en una unidad de cuidados intensivos, la neutropenia, la diabetes, la cirugía abdominal y la utilización de catéter venoso central. Los agentes antifúngicos más utilizados para tratarla son las equinocandinas, pero determinados aislamientos son resistentes a dichos componentes, por lo que algunos pacientes no responden al tratamiento. Objetivos. Este trabajo tiene como objetivo evaluar la sensibilidad in vitro de varios aislamientos de Candida procedentes de muestras de sangre y realizar su caracterización molecular. Métodos. Se hicieron pruebas de sensibilidad a los antifúngicos mediante el método de microdilución en caldo. Para la caracterización molecular se utilizó la secuenciación de las regiones ITS y D1/D2 del DNAr. Resultados. De los 80 aislamientos evaluados, 74 fueron sensibles a la anidulafungina, 5 mostraron sensibilidad intermedia y solo uno era resistente. Cuando se utilizó la micafungina, 67 aislamientos resultaron sensibles, 8 presentaron sensibilidad intermedia y 5 fueron resistentes. Los 80 aislamientos fueron sensibles a la anfotericina B. Al menos 65 aislamientos eran sensibles al fluconazol, 8 presentaron sensibilidad dependiente de la dosis y 4 se mostraron resistentes. La identificación molecular confirmó la identificación fenotípica en un 91,3% de los aislamientos. Conclusiones. Teniendo en cuenta los resultados obtenidos con las pruebas de sensibilidad a los antifúngicos, estas resultan indispensables para el tratamiento adecuado de la candidemia. Se concluye además que la identificación molecular proporciona una identificación precisa y consigue identificar la variabilidad genética de las especies del género Candida aisladas en pacientes con candidemia (AU)


Subject(s)
Humans , Candida/pathogenicity , Candidiasis/drug therapy , Candidemia/drug therapy , Candidiasis, Invasive/drug therapy , Antifungal Agents/therapeutic use , In Vitro Techniques/methods , Microbial Sensitivity Tests
6.
Rev Iberoam Micol ; 32(4): 221-8, 2015.
Article in English | MEDLINE | ID: mdl-25681153

ABSTRACT

BACKGROUND: Candida species are the main cause of hospital acquired fungal bloodstream infections. The main risk factors for candidemia include parenteral nutrition, long-term intensive care, neutropenia, diabetes, abdominal surgery and the use of central venous catheters. The antifungal drugs used to treat candidemia are mainly the echinocandins, however some isolates may be resistant to these drugs. AIMS: This work aims to evaluate the in vitro susceptibility patterns of various Candida species isolated from blood samples and provide their identification by molecular characterization. METHODS: Antifungal susceptibility testing was performed using the broth microdilution method. The sequencing of the ITS and D1/D2 regions of rDNA was used for molecular characterization. RESULTS: Seventy-four of the 80 isolates were susceptible to anidulafungin, 5 were intermediate, and 1 was resistant. For micafungin 67 were susceptible, 8 were intermediate and 5 were resistant. All isolates were susceptible to amphotericin B. Lastly, 65 isolates were susceptible to fluconazole, 8 were dose-dependent and 4 were resistant. The molecular identification corroborated the phenotypic data in 91.3% of the isolates. CONCLUSIONS: Antifungal susceptibility data has an important role in the treatment of candidemia episodes. It was also concluded that the molecular analysis of isolates provides an accurate identification and identifies genetic variability within Candida species isolated from patients with candidemia.


Subject(s)
Antifungal Agents/pharmacology , Candida/isolation & purification , Candidemia/microbiology , Drug Resistance, Fungal , Antifungal Agents/therapeutic use , Candida/classification , Candida/drug effects , Candida/genetics , Candidemia/drug therapy , Candidemia/epidemiology , DNA, Fungal/genetics , DNA, Fungal/isolation & purification , Drug Resistance, Fungal/genetics , Genes, Fungal , Humans , Likelihood Functions , Microbial Sensitivity Tests , Phylogeny , Spain/epidemiology , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...